J
James M. Markert
Researcher at University of Alabama at Birmingham
Publications - 209
Citations - 10342
James M. Markert is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Oncolytic virus & Glioma. The author has an hindex of 43, co-authored 192 publications receiving 8819 citations. Previous affiliations of James M. Markert include University of Michigan & University of British Columbia.
Papers
More filters
Journal ArticleDOI
Experimental therapy of human glioma by means of a genetically engineered virus mutant
TL;DR: A thymidine kinase-negative mutant of herpes simplex virus-1 (dlsptk) that is attenuated for neurovirulence was tested as a possible treatment for gliomas and merit further evaluation as novel antineoplastic agents.
Journal ArticleDOI
Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.
James M. Markert,M D Medlock,Samuel D. Rabkin,George Yancey Gillespie,Tomoki Todo,William D. Hunter,Cheryl A. Palmer,F Feigenbaum,C Tornatore,F Tufaro,Robert L. Martuza +10 more
TL;DR: Radiographic and neuropathologic evidence suggestive of anti-tumor activity and long-term presence of viral DNA in some cases is found, and no toxicity or serious adverse events could unequivocally be ascribed to G207.
Journal ArticleDOI
A Phase I Open-Label, Dose-Escalation, Multi-Institutional Trial of Injection with an E1B-Attenuated Adenovirus, ONYX-015, into the Peritumoral Region of Recurrent Malignant Gliomas, in the Adjuvant Setting
E. Antonio Chiocca,Khalid M. Abbed,Stephen B. Tatter,David N. Louis,Fred H. Hochberg,Fred G. Barker,Jean Kracher,Stuart A. Grossman,Joy D. Fisher,Kathryn A. Carson,Mark L. Rosenblum,Tom Mikkelsen,Jeffrey J. Olson,James M. Markert,Steven S. Rosenfeld,L. Burt Nabors,Steven Brem,Surasak Phuphanich,Scott Freeman,Richard Kaplan,James A. Zwiebel +20 more
TL;DR: Injection of ONYX-015 into glioma cavities is well tolerated at doses up to 10(10) pfu, and in patients who underwent a second resection 3 months after ONYx-015 injection, a lymphocytic and plasmacytoid cell infiltrate was observed.
Journal ArticleDOI
Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM.
James M. Markert,Peter Liechty,Wenquan Wang,Shanna Gaston,Eunice Braz,Matthias Karrasch,Louis B. Nabors,Michael Markiewicz,Alfred D. Lakeman,Cheryl A. Palmer,Jacqueline N. Parker,Richard J. Whitley,George Yancey Gillespie +12 more
TL;DR: G207 appears safe for multiple dose delivery, including direct inoculation into the brain surrounding tumor resection cavity, and Radiographic and neuropathologic evidence suggestive of antitumor activity is reported.
Journal ArticleDOI
Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors
Jacqueline N. Parker,George Yancey Gillespie,Love Ce,Randall S,Richard J. Whitley,James M. Markert +5 more
TL;DR: Construction of a conditionally replication-competent mutant expressing both subunits of mIL-12 (M002) and its evaluation in a syngeneic neuroblastoma murine model conclude that M002 produced a survival benefit via oncolytic effects combined with immunologic effects meditated by helper T cells of subset type 1.